These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

397 related articles for article (PubMed ID: 15503297)

  • 1. Ifosfamide, carboplatin, and etoposide (ICE) reinduction chemotherapy in a large cohort of children and adolescents with recurrent/refractory sarcoma: the Children's Cancer Group (CCG) experience.
    Van Winkle P; Angiolillo A; Krailo M; Cheung YK; Anderson B; Davenport V; Reaman G; Cairo MS
    Pediatr Blood Cancer; 2005 Apr; 44(4):338-47. PubMed ID: 15503297
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Phase I study of granulocyte-macrophage-colony stimulating factor/interleukin-3 fusion protein (PIXY321) following ifosfamide, carboplatin, and etoposide therapy for children with recurrent or refractory solid tumors: a report of the Children's Cancer Group.
    Cairo MS; Krailo MD; Weinthal JA; Secola R; Bergeron S; van de Ven C; Blazar BR; Garrison L; Reaman GH
    Cancer; 1998 Oct; 83(7):1449-60. PubMed ID: 9762948
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase I clinical, pharmacologic, and biologic study of thrombopoietin and granulocyte colony-stimulating factor in children receiving ifosfamide, carboplatin, and etoposide chemotherapy for recurrent or refractory solid tumors: a Children's Oncology Group experience.
    Angiolillo AL; Davenport V; Bonilla MA; van de Ven C; Ayello J; Militano O; Miller LL; Krailo M; Reaman G; Cairo MS;
    Clin Cancer Res; 2005 Apr; 11(7):2644-50. PubMed ID: 15814645
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of ICE (ifosfamide-carboplatin-etoposide) versus DHAP (cytosine arabinoside-cisplatin-dexamethasone) as salvage chemotherapy in patients with relapsed or refractory lymphoma.
    Abali H; Urün Y; Oksüzoğlu B; Budakoğlu B; Yildirim N; Güler T; Ozet G; Zengin N
    Cancer Invest; 2008 May; 26(4):401-6. PubMed ID: 18443961
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cooperative trial CWS-91 for localized soft tissue sarcoma in children, adolescents, and young adults.
    Dantonello TM; Int-Veen C; Harms D; Leuschner I; Schmidt BF; Herbst M; Juergens H; Scheel-Walter HG; Bielack SS; Klingebiel T; Dickerhoff R; Kirsch S; Brecht I; Schmelzle R; Greulich M; Gadner H; Greiner J; Marky I; Treuner J; Koscielniak E
    J Clin Oncol; 2009 Mar; 27(9):1446-55. PubMed ID: 19224858
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of consolidation high-dose chemotherapy with ifosfamide, carboplatin and etoposide (HD-ICE) followed by autologous peripheral blood stem cell rescue in chemosensitive patients with metastatic soft tissue sarcomas.
    Schlemmer M; Wendtner CM; Falk M; Abdel-Rahman S; Licht T; Baumert J; Straka C; Hentrich M; Salat C; Hiddemann W; Issels RD
    Oncology; 2006; 71(1-2):32-9. PubMed ID: 17344669
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High histologic and overall response to dose intensification of ifosfamide, carboplatin, and etoposide with cyclophosphamide, doxorubicin, and vincristine in patients with high-risk Ewing sarcoma family tumors: the Bambino Gesù Children's Hospital experience.
    Milano GM; Cozza R; Ilari I; De Sio L; Boldrini R; Jenkner A; De Ioris M; Inserra A; Dominici C; Donfrancesco A
    Cancer; 2006 Apr; 106(8):1838-45. PubMed ID: 16532434
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Concomitant administration of vincristine, doxorubicin, cyclophosphamide, ifosfamide, and etoposide for high-risk sarcomas: the St. Jude Children's Research Hospital experience.
    Navid F; Santana VM; Billups CA; Merchant TE; Furman WL; Spunt SL; Cain AM; Rao BN; Hale GA; Pappo AS
    Cancer; 2006 Apr; 106(8):1846-56. PubMed ID: 16541446
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prospective randomized trial between two doses of granulocyte colony-stimulating factor after ifosfamide, carboplatin, and etoposide in children with recurrent or refractory solid tumors: a children's cancer group report.
    Cairo MS; Shen V; Krailo MD; Bauer M; Miser JS; Sato JK; Blatt J; Blazar BR; Frierdich S; Liu-Mares W; Reaman GH
    J Pediatr Hematol Oncol; 2001 Jan; 23(1):30-8. PubMed ID: 11196267
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II trial of topotecan administered as 72-hour continuous infusion in children with refractory solid tumors: a collaborative Pediatric Branch, National Cancer Institute, and Children's Cancer Group Study.
    Blaney SM; Needle MN; Gillespie A; Sato JK; Reaman GH; Berg SL; Adamson PC; Krailo MD; Bleyer WA; Poplack DG; Balis FM
    Clin Cancer Res; 1998 Feb; 4(2):357-60. PubMed ID: 9516923
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomized comparison of intensified six-drug versus standard three-drug chemotherapy for high-risk nonmetastatic rhabdomyosarcoma and other chemotherapy-sensitive childhood soft tissue sarcomas: long-term results from the International Society of Pediatric Oncology MMT95 study.
    Oberlin O; Rey A; Sanchez de Toledo J; Martelli H; Jenney ME; Scopinaro M; Bergeron C; Merks JH; Bouvet N; Ellershaw C; Kelsey A; Spooner D; Stevens MC
    J Clin Oncol; 2012 Jul; 30(20):2457-65. PubMed ID: 22665534
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oral etoposide for recurrent/progressive sarcomas of childhood.
    Kebudi R; Görgün O; Ayan I
    Pediatr Blood Cancer; 2004 Apr; 42(4):320-4. PubMed ID: 14966827
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ifosfamide in the treatment of soft-tissue sarcomas: experience at the West German Tumor Center, Essen.
    Schütte J; Kellner R; Seeber S
    Cancer Chemother Pharmacol; 1993; 31 Suppl 2():S194-8. PubMed ID: 8453697
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Soft tissue sarcoma or malignant mesenchymal tumors in the first year of life: experience of the International Society of Pediatric Oncology (SIOP) Malignant Mesenchymal Tumor Committee.
    Orbach D; Rey A; Oberlin O; Sanchez de Toledo J; Terrier-Lacombe MJ; van Unnik A; Quintana E; Stevens MC
    J Clin Oncol; 2005 Jul; 23(19):4363-71. PubMed ID: 15994146
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Southwest Oncology Group and Cancer and Leukemia Group B phase II study of doxorubicin, dacarbazine, ifosfamide, and mesna in adults with advanced osteosarcoma, Ewing's sarcoma, and rhabdomyosarcoma.
    Antman K; Crowley J; Balcerzak SP; Kempf RA; Weiss RB; Clamon GH; Baker LH
    Cancer; 1998 Apr; 82(7):1288-95. PubMed ID: 9529020
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activity of postoperative carboplatin, etoposide, and high-dose methotrexate in pediatric CNS embryonal tumors: results of a phase II study in newly diagnosed children.
    Kellie SJ; Wong CK; Pozza LD; Waters KD; Lockwood L; Mauger DC; White L
    Med Pediatr Oncol; 2002 Sep; 39(3):168-74. PubMed ID: 12210445
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Refining therapeutic strategies for patients with resistant Wilm's tumor.
    Marina NM; Wilimas JA; Meyer WH; Jones DP; Douglass EC; Pratt CB
    Am J Pediatr Hematol Oncol; 1994 Nov; 16(4):296-300. PubMed ID: 7978044
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Myeloablative chemotherapy with autologous peripheral blood stem cell transplantation in patients with poor-prognosis solid tumors - Bulgarian experience.
    Avramova B; Jordanova M; Michailov G; Konstantinov D; Christosova I; Bobev D
    J BUON; 2006; 11(4):433-8. PubMed ID: 17309174
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Topotecan by 21-day continuous infusion in children with relapsed or refractory solid tumors: a Children's Oncology Group study.
    Hawkins DS; Bradfield S; Whitlock JA; Krailo M; Franklin J; Blaney SM; Adamson PC; Reaman G
    Pediatr Blood Cancer; 2006 Nov; 47(6):790-4. PubMed ID: 16435380
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A threefold dose intensity treatment with ifosfamide, carboplatin, and etoposide for patients with small cell lung cancer: a randomized trial.
    Leyvraz S; Pampallona S; Martinelli G; Ploner F; Perey L; Aversa S; Peters S; Brunsvig P; Montes A; Lange A; Yilmaz U; Rosti G;
    J Natl Cancer Inst; 2008 Apr; 100(8):533-41. PubMed ID: 18398095
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.